Report Detail
Global Bispecific Antibodies for Solid Tumor Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032
- RnM4677880 |
- 26 February, 2026 |
- Global |
- 90 Pages |
- GIR |
- Pharma & Healthcare
According to our (Global Info Research) latest study, the global Bispecific Antibodies for Solid Tumor market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
Bispecific antibodies for solid tumors refer to a type of therapeutic antibody that is designed to recognize and bind two different targets on the surface of cancer cells. This approach is particularly relevant for solid tumors, which are often resistant to traditional single-target therapies. By having two different targets, bispecific antibodies are able to simultaneously engage both cancer cells and surrounding immune cells, triggering an immune response against the tumor. This dual-targeting approach can help to overcome some of the mechanisms that solid tumors use to evade immune detection, such as by downregulating expression of single target antigens or upregulating checkpoint regulators.Bispecific antibodies can also be designed to promote direct cell killing of cancer cells through recruitment and activation of immune cells, such as T-cells and Natural Killer (NK) cells. This mechanism of action can help to overcome resistance to cell death induced by single-target therapies.Recent advances in the development of bispecific antibodies have led to the availability of several FDA-approved molecules for the treatment of solid tumors, such as Catumaxomab for malignant ascites in ovarian cancer and Blinatumamab for certain types of leukemia. Many more bispecific antibodies are currently being evaluated in clinical trials for solid tumors, and are expected to have a significant impact on the treatment of cancer in the future.
This report is a detailed and comprehensive analysis for global Bispecific Antibodies for Solid Tumor market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Bispecific Antibodies for Solid Tumor market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Bispecific Antibodies for Solid Tumor market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Bispecific Antibodies for Solid Tumor market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Bispecific Antibodies for Solid Tumor market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Bispecific Antibodies for Solid Tumor
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Bispecific Antibodies for Solid Tumor market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Amgen, Genmab, Roche, BeiGene, Astellas Pharma, Johnson & Johnson, Akeso Biopharma, Abbvie, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Bispecific Antibodies for Solid Tumor market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Bispecific Antibodies without Fc
Bispecific Antibodies with Fc
Market segment by Application
Cervical Cancer
Lung Cancer
Head and Neck Squamous Carcinoma
Stomach Cancer
Breast Cancer
Others
Major players covered
Amgen
Genmab
Roche
BeiGene
Astellas Pharma
Johnson & Johnson
Akeso Biopharma
Abbvie
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Bispecific Antibodies for Solid Tumor product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Bispecific Antibodies for Solid Tumor, with price, sales quantity, revenue, and global market share of Bispecific Antibodies for Solid Tumor from 2021 to 2026.
Chapter 3, the Bispecific Antibodies for Solid Tumor competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Bispecific Antibodies for Solid Tumor breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Bispecific Antibodies for Solid Tumor market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Bispecific Antibodies for Solid Tumor.
Chapter 14 and 15, to describe Bispecific Antibodies for Solid Tumor sales channel, distributors, customers, research findings and conclusion.
1 Market Overview
- 1.1 Product Overview and Scope
- 1.2 Market Estimation Caveats and Base Year
- 1.3 Market Analysis by Type
- 1.3.1 Overview: Global Bispecific Antibodies for Solid Tumor Consumption Value by Type: 2021 Versus 2025 Versus 2032
- 1.3.2 Bispecific Antibodies without Fc
- 1.3.3 Bispecific Antibodies with Fc
- 1.4 Market Analysis by Application
- 1.4.1 Overview: Global Bispecific Antibodies for Solid Tumor Consumption Value by Application: 2021 Versus 2025 Versus 2032
- 1.4.2 Cervical Cancer
- 1.4.3 Lung Cancer
- 1.4.4 Head and Neck Squamous Carcinoma
- 1.4.5 Stomach Cancer
- 1.4.6 Breast Cancer
- 1.4.7 Others
- 1.5 Global Bispecific Antibodies for Solid Tumor Market Size & Forecast
- 1.5.1 Global Bispecific Antibodies for Solid Tumor Consumption Value (2021 & 2025 & 2032)
- 1.5.2 Global Bispecific Antibodies for Solid Tumor Sales Quantity (2021-2032)
- 1.5.3 Global Bispecific Antibodies for Solid Tumor Average Price (2021-2032)
2 Manufacturers Profiles
- 2.1 Amgen
- 2.1.1 Amgen Details
- 2.1.2 Amgen Major Business
- 2.1.3 Amgen Bispecific Antibodies for Solid Tumor Product and Services
- 2.1.4 Amgen Bispecific Antibodies for Solid Tumor Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.1.5 Amgen Recent Developments/Updates
- 2.2 Genmab
- 2.2.1 Genmab Details
- 2.2.2 Genmab Major Business
- 2.2.3 Genmab Bispecific Antibodies for Solid Tumor Product and Services
- 2.2.4 Genmab Bispecific Antibodies for Solid Tumor Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.2.5 Genmab Recent Developments/Updates
- 2.3 Roche
- 2.3.1 Roche Details
- 2.3.2 Roche Major Business
- 2.3.3 Roche Bispecific Antibodies for Solid Tumor Product and Services
- 2.3.4 Roche Bispecific Antibodies for Solid Tumor Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.3.5 Roche Recent Developments/Updates
- 2.4 BeiGene
- 2.4.1 BeiGene Details
- 2.4.2 BeiGene Major Business
- 2.4.3 BeiGene Bispecific Antibodies for Solid Tumor Product and Services
- 2.4.4 BeiGene Bispecific Antibodies for Solid Tumor Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.4.5 BeiGene Recent Developments/Updates
- 2.5 Astellas Pharma
- 2.5.1 Astellas Pharma Details
- 2.5.2 Astellas Pharma Major Business
- 2.5.3 Astellas Pharma Bispecific Antibodies for Solid Tumor Product and Services
- 2.5.4 Astellas Pharma Bispecific Antibodies for Solid Tumor Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.5.5 Astellas Pharma Recent Developments/Updates
- 2.6 Johnson & Johnson
- 2.6.1 Johnson & Johnson Details
- 2.6.2 Johnson & Johnson Major Business
- 2.6.3 Johnson & Johnson Bispecific Antibodies for Solid Tumor Product and Services
- 2.6.4 Johnson & Johnson Bispecific Antibodies for Solid Tumor Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.6.5 Johnson & Johnson Recent Developments/Updates
- 2.7 Akeso Biopharma
- 2.7.1 Akeso Biopharma Details
- 2.7.2 Akeso Biopharma Major Business
- 2.7.3 Akeso Biopharma Bispecific Antibodies for Solid Tumor Product and Services
- 2.7.4 Akeso Biopharma Bispecific Antibodies for Solid Tumor Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.7.5 Akeso Biopharma Recent Developments/Updates
- 2.8 Abbvie
- 2.8.1 Abbvie Details
- 2.8.2 Abbvie Major Business
- 2.8.3 Abbvie Bispecific Antibodies for Solid Tumor Product and Services
- 2.8.4 Abbvie Bispecific Antibodies for Solid Tumor Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.8.5 Abbvie Recent Developments/Updates
3 Competitive Environment: Bispecific Antibodies for Solid Tumor by Manufacturer
- 3.1 Global Bispecific Antibodies for Solid Tumor Sales Quantity by Manufacturer (2021-2026)
- 3.2 Global Bispecific Antibodies for Solid Tumor Revenue by Manufacturer (2021-2026)
- 3.3 Global Bispecific Antibodies for Solid Tumor Average Price by Manufacturer (2021-2026)
- 3.4 Market Share Analysis (2025)
- 3.4.1 Producer Shipments of Bispecific Antibodies for Solid Tumor by Manufacturer Revenue ($MM) and Market Share (%): 2025
- 3.4.2 Top 3 Bispecific Antibodies for Solid Tumor Manufacturer Market Share in 2025
- 3.4.3 Top 6 Bispecific Antibodies for Solid Tumor Manufacturer Market Share in 2025
- 3.5 Bispecific Antibodies for Solid Tumor Market: Overall Company Footprint Analysis
- 3.5.1 Bispecific Antibodies for Solid Tumor Market: Region Footprint
- 3.5.2 Bispecific Antibodies for Solid Tumor Market: Company Product Type Footprint
- 3.5.3 Bispecific Antibodies for Solid Tumor Market: Company Product Application Footprint
- 3.6 New Market Entrants and Barriers to Market Entry
- 3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
- 4.1 Global Bispecific Antibodies for Solid Tumor Market Size by Region
- 4.1.1 Global Bispecific Antibodies for Solid Tumor Sales Quantity by Region (2021-2032)
- 4.1.2 Global Bispecific Antibodies for Solid Tumor Consumption Value by Region (2021-2032)
- 4.1.3 Global Bispecific Antibodies for Solid Tumor Average Price by Region (2021-2032)
- 4.2 North America Bispecific Antibodies for Solid Tumor Consumption Value (2021-2032)
- 4.3 Europe Bispecific Antibodies for Solid Tumor Consumption Value (2021-2032)
- 4.4 Asia-Pacific Bispecific Antibodies for Solid Tumor Consumption Value (2021-2032)
- 4.5 South America Bispecific Antibodies for Solid Tumor Consumption Value (2021-2032)
- 4.6 Middle East & Africa Bispecific Antibodies for Solid Tumor Consumption Value (2021-2032)
5 Market Segment by Type
- 5.1 Global Bispecific Antibodies for Solid Tumor Sales Quantity by Type (2021-2032)
- 5.2 Global Bispecific Antibodies for Solid Tumor Consumption Value by Type (2021-2032)
- 5.3 Global Bispecific Antibodies for Solid Tumor Average Price by Type (2021-2032)
6 Market Segment by Application
- 6.1 Global Bispecific Antibodies for Solid Tumor Sales Quantity by Application (2021-2032)
- 6.2 Global Bispecific Antibodies for Solid Tumor Consumption Value by Application (2021-2032)
- 6.3 Global Bispecific Antibodies for Solid Tumor Average Price by Application (2021-2032)
7 North America
- 7.1 North America Bispecific Antibodies for Solid Tumor Sales Quantity by Type (2021-2032)
- 7.2 North America Bispecific Antibodies for Solid Tumor Sales Quantity by Application (2021-2032)
- 7.3 North America Bispecific Antibodies for Solid Tumor Market Size by Country
- 7.3.1 North America Bispecific Antibodies for Solid Tumor Sales Quantity by Country (2021-2032)
- 7.3.2 North America Bispecific Antibodies for Solid Tumor Consumption Value by Country (2021-2032)
- 7.3.3 United States Market Size and Forecast (2021-2032)
- 7.3.4 Canada Market Size and Forecast (2021-2032)
- 7.3.5 Mexico Market Size and Forecast (2021-2032)
8 Europe
- 8.1 Europe Bispecific Antibodies for Solid Tumor Sales Quantity by Type (2021-2032)
- 8.2 Europe Bispecific Antibodies for Solid Tumor Sales Quantity by Application (2021-2032)
- 8.3 Europe Bispecific Antibodies for Solid Tumor Market Size by Country
- 8.3.1 Europe Bispecific Antibodies for Solid Tumor Sales Quantity by Country (2021-2032)
- 8.3.2 Europe Bispecific Antibodies for Solid Tumor Consumption Value by Country (2021-2032)
- 8.3.3 Germany Market Size and Forecast (2021-2032)
- 8.3.4 France Market Size and Forecast (2021-2032)
- 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
- 8.3.6 Russia Market Size and Forecast (2021-2032)
- 8.3.7 Italy Market Size and Forecast (2021-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Bispecific Antibodies for Solid Tumor Sales Quantity by Type (2021-2032)
- 9.2 Asia-Pacific Bispecific Antibodies for Solid Tumor Sales Quantity by Application (2021-2032)
- 9.3 Asia-Pacific Bispecific Antibodies for Solid Tumor Market Size by Region
- 9.3.1 Asia-Pacific Bispecific Antibodies for Solid Tumor Sales Quantity by Region (2021-2032)
- 9.3.2 Asia-Pacific Bispecific Antibodies for Solid Tumor Consumption Value by Region (2021-2032)
- 9.3.3 China Market Size and Forecast (2021-2032)
- 9.3.4 Japan Market Size and Forecast (2021-2032)
- 9.3.5 South Korea Market Size and Forecast (2021-2032)
- 9.3.6 India Market Size and Forecast (2021-2032)
- 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
- 9.3.8 Australia Market Size and Forecast (2021-2032)
10 South America
- 10.1 South America Bispecific Antibodies for Solid Tumor Sales Quantity by Type (2021-2032)
- 10.2 South America Bispecific Antibodies for Solid Tumor Sales Quantity by Application (2021-2032)
- 10.3 South America Bispecific Antibodies for Solid Tumor Market Size by Country
- 10.3.1 South America Bispecific Antibodies for Solid Tumor Sales Quantity by Country (2021-2032)
- 10.3.2 South America Bispecific Antibodies for Solid Tumor Consumption Value by Country (2021-2032)
- 10.3.3 Brazil Market Size and Forecast (2021-2032)
- 10.3.4 Argentina Market Size and Forecast (2021-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Bispecific Antibodies for Solid Tumor Sales Quantity by Type (2021-2032)
- 11.2 Middle East & Africa Bispecific Antibodies for Solid Tumor Sales Quantity by Application (2021-2032)
- 11.3 Middle East & Africa Bispecific Antibodies for Solid Tumor Market Size by Country
- 11.3.1 Middle East & Africa Bispecific Antibodies for Solid Tumor Sales Quantity by Country (2021-2032)
- 11.3.2 Middle East & Africa Bispecific Antibodies for Solid Tumor Consumption Value by Country (2021-2032)
- 11.3.3 Turkey Market Size and Forecast (2021-2032)
- 11.3.4 Egypt Market Size and Forecast (2021-2032)
- 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
- 11.3.6 South Africa Market Size and Forecast (2021-2032)
12 Market Dynamics
- 12.1 Bispecific Antibodies for Solid Tumor Market Drivers
- 12.2 Bispecific Antibodies for Solid Tumor Market Restraints
- 12.3 Bispecific Antibodies for Solid Tumor Trends Analysis
- 12.4 Porters Five Forces Analysis
- 12.4.1 Threat of New Entrants
- 12.4.2 Bargaining Power of Suppliers
- 12.4.3 Bargaining Power of Buyers
- 12.4.4 Threat of Substitutes
- 12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
- 13.1 Raw Material of Bispecific Antibodies for Solid Tumor and Key Manufacturers
- 13.2 Manufacturing Costs Percentage of Bispecific Antibodies for Solid Tumor
- 13.3 Bispecific Antibodies for Solid Tumor Production Process
- 13.4 Industry Value Chain Analysis
14 Shipments by Distribution Channel
- 14.1 Sales Channel
- 14.1.1 Direct to End-User
- 14.1.2 Distributors
- 14.2 Bispecific Antibodies for Solid Tumor Typical Distributors
- 14.3 Bispecific Antibodies for Solid Tumor Typical Customers
15 Research Findings and Conclusion
16 Appendix
- 16.1 Methodology
- 16.2 Research Process and Data Source
Summary:
Get latest Market Research Reports on Bispecific Antibodies for Solid Tumor. Industry analysis & Market Report on Bispecific Antibodies for Solid Tumor is a syndicated market report, published as Global Bispecific Antibodies for Solid Tumor Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Bispecific Antibodies for Solid Tumor market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
